|
Canada-0-IMPRINTING 公司名錄
|
公司新聞:
- Prognostic and predictive markers of systemic sclerosis-associated . . .
To explore prognostic and predictive markers of SSc-associated interstitial lung disease (SSc-ILD) outcomes in a phase 3 trial (focuSSced) and prognostic markers in a real-world cohort (SMART)
- Systemic Sclerosis-Associated Interstitial Lung Disease
Interstitial lung disease (ILD) affects 40% to 60% of patients with systemic sclerosis (SSc) and represents the leading cause of death Although treatment options for SSc with ILD remain limited, randomized controlled trials have demonstrated the safety and efficacy of approved and unapproved therapies However, numerous unanswered questions remain regarding management of SSc with ILD, and 3
- Systemic Sclerosis-Associated Interstitial Lung Disease: Current . . .
SSc-ILD trials tend to enroll patients with relatively early disease (often < 5–7 years from onset) and evidence of ILD on HRCT (high-resolution computed tomography) A majority of participants have diffused cutaneous SSc (in trials focusing on SSc) and moderate lung impairment at baseline (mean FVC around 65%–80% predicted)
- Treatment of Systemic Sclerosis–associated Interstitial Lung Disease . . .
Background: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in patients with systemic sclerosis (SSc) To date, clinical practice guidelines regarding treatment for patients with SSc-ILD are primarily consensus based
- State-of-the-art evidence in the treatment of systemic sclerosis
Pope et al review the current management (including both screening and treatment) of organ-based manifestations of systemic sclerosis as well as overall disease modification, with a focus on
- Systemic sclerosis-associated interstitial lung disease
Currently, interstitial lung disease is the most common cause of death among patients with systemic sclerosis, with a prevalence of up to 30% and a 10-year mortality of up to 40% Interstitial lung disease is more common among African Americans and in people with the difuse cutaneous form of systemic sclerosis or anti-topoisomerase 1 antibodies
- Predictors of progression in systemic sclerosis patients with . . .
Once diagnosed with SSc-ILD, patients' clinical courses are variable and difficult to predict, though certain patient characteristics and biomarkers are associated with disease progression
- Predictors of progression in systemic sclerosis patients with . . .
In the recently published Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial, patients with SSc-ILD treated with nintedanib had a lower rate of annual FVC decline than those receiving placebo (treatment difference 41 mL) [86]
|
|